Jimin Kexin

Jimin Kexin was founded in 1999, with a pharmaceutical history dating back to the 1950s. It currently has over 12,000 employees and is headquartered in Nanchang, China, with industrial platforms and R&D institutions in Jiangxi, Beijing, Shanghai, Jiangsu, and Zhejiang. In 2017, the Group's operating revenue exceeded RMB 23.7 billion, ranking 6th among China's top 100 pharmaceutical companies and 10th among China's top 100 pharmaceutical industrial enterprises.
Adhering to an innovation-driven strategic approach, the company focuses on the R&D, production, and sales of modern Chinese medicines, chemical drugs, biological preparations, and health products. It owns 7 pharmaceutical bases, 1 international-level postdoctoral workstation, 1 CNAS-certified laboratory, and 2 provincial-level engineering technology centers, and has established new drug R&D teams overseas. At present, the Group has achieved fruitful results in the fields of cardio-cerebrovascular, renal, oncology, anti-infection, and emergency medicines. Core products such as "Jinshuibao", "Xingnaojing", "Kanglaite", "Xineng", "Lixing", "Huangshi Xiangsheng Pill", and "Jiuhua Hemorrhoid Suppository" have a relatively high market share in their respective national sub-categories.
Jimin Kexin has always adhered to its corporate mission of "Benefiting the people, earning trust worldwide", actively devoting itself to social public welfare and charity. Its cumulative charitable donations amount to RMB 317 million, and it has been awarded the "China Charity Outstanding Contribution Award" by the China Charity Federation. Looking ahead, Jimin Kexin will continue to provide trustworthy pharmaceutical products and diagnostic and treatment services, making unremitting efforts to improve human health and quality of life!